Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eye Diseases | 4 | 2026 | 100 | 0.960 |
Why?
|
| Graves Ophthalmopathy | 2 | 2022 | 13 | 0.860 |
Why?
|
| Exophthalmos | 2 | 2022 | 18 | 0.850 |
Why?
|
| Eyelid Diseases | 2 | 2022 | 26 | 0.830 |
Why?
|
| Drug Costs | 2 | 2016 | 116 | 0.810 |
Why?
|
| Health Care Costs | 2 | 2016 | 423 | 0.700 |
Why?
|
| Ophthalmologists | 2 | 2020 | 21 | 0.640 |
Why?
|
| Methotrexate | 2 | 2016 | 234 | 0.550 |
Why?
|
| Hemifacial Spasm | 1 | 2018 | 2 | 0.540 |
Why?
|
| Blepharospasm | 1 | 2018 | 7 | 0.540 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2016 | 1408 | 0.530 |
Why?
|
| Botulinum Toxins | 1 | 2018 | 49 | 0.500 |
Why?
|
| Rheumatologists | 1 | 2016 | 15 | 0.490 |
Why?
|
| Behcet Syndrome | 1 | 2016 | 19 | 0.480 |
Why?
|
| Azathioprine | 1 | 2016 | 43 | 0.480 |
Why?
|
| Arthritis, Juvenile | 1 | 2016 | 64 | 0.450 |
Why?
|
| Ophthalmology | 4 | 2026 | 122 | 0.450 |
Why?
|
| Glucocorticoids | 2 | 2016 | 536 | 0.440 |
Why?
|
| Insurance, Health | 2 | 2016 | 318 | 0.440 |
Why?
|
| Uveitis, Posterior | 1 | 2014 | 12 | 0.430 |
Why?
|
| Uveitis, Intermediate | 1 | 2014 | 8 | 0.420 |
Why?
|
| Uveitis | 1 | 2016 | 152 | 0.420 |
Why?
|
| Vision Disorders | 1 | 2016 | 179 | 0.420 |
Why?
|
| Eyelid Neoplasms | 2 | 2024 | 11 | 0.380 |
Why?
|
| Referral and Consultation | 2 | 2026 | 881 | 0.250 |
Why?
|
| Corneal Diseases | 1 | 2025 | 48 | 0.210 |
Why?
|
| Specialization | 2 | 2016 | 137 | 0.210 |
Why?
|
| Mohs Surgery | 1 | 2024 | 30 | 0.200 |
Why?
|
| Cornea | 1 | 2025 | 156 | 0.200 |
Why?
|
| Patient Transfer | 1 | 2026 | 224 | 0.190 |
Why?
|
| Academic Medical Centers | 1 | 2026 | 561 | 0.190 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2022 | 2 | 0.190 |
Why?
|
| Eye Hemorrhage | 1 | 2022 | 3 | 0.190 |
Why?
|
| Surgical Flaps | 1 | 2024 | 140 | 0.180 |
Why?
|
| Visual Acuity | 1 | 2025 | 499 | 0.180 |
Why?
|
| Blepharitis | 1 | 2022 | 8 | 0.170 |
Why?
|
| Electronic Health Records | 2 | 2020 | 1210 | 0.170 |
Why?
|
| Keratitis | 1 | 2022 | 21 | 0.170 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 829 | 0.170 |
Why?
|
| Ophthalmoplegia | 1 | 2021 | 12 | 0.170 |
Why?
|
| Emergency Service, Hospital | 2 | 2026 | 2363 | 0.170 |
Why?
|
| Trochlear Nerve Diseases | 1 | 2021 | 8 | 0.170 |
Why?
|
| Cavernous Sinus | 1 | 2021 | 16 | 0.170 |
Why?
|
| Mucormycosis | 1 | 2021 | 18 | 0.170 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2021 | 9 | 0.170 |
Why?
|
| Population Health | 1 | 2021 | 44 | 0.170 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 6073 | 0.160 |
Why?
|
| Orbital Diseases | 1 | 2021 | 37 | 0.160 |
Why?
|
| Coinfection | 1 | 2021 | 143 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2022 | 992 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 486 | 0.130 |
Why?
|
| Decision Making | 2 | 2016 | 993 | 0.130 |
Why?
|
| Triage | 1 | 2020 | 243 | 0.130 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 317 | 0.130 |
Why?
|
| Injections | 1 | 2018 | 201 | 0.130 |
Why?
|
| Humans | 17 | 2026 | 146342 | 0.120 |
Why?
|
| Administration, Topical | 1 | 2016 | 154 | 0.120 |
Why?
|
| Rheumatology | 1 | 2016 | 136 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 806 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2016 | 541 | 0.100 |
Why?
|
| United States | 4 | 2026 | 16136 | 0.100 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 365 | 0.090 |
Why?
|
| Quality of Life | 1 | 2025 | 3200 | 0.090 |
Why?
|
| Health Surveys | 1 | 2014 | 511 | 0.090 |
Why?
|
| Middle Aged | 5 | 2026 | 36619 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2026 | 17438 | 0.090 |
Why?
|
| Female | 8 | 2026 | 79499 | 0.090 |
Why?
|
| Patient Selection | 1 | 2016 | 728 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2016 | 701 | 0.080 |
Why?
|
| Adult | 4 | 2026 | 41087 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 5899 | 0.070 |
Why?
|
| Male | 6 | 2026 | 73396 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2024 | 706 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2020 | 8123 | 0.060 |
Why?
|
| Blepharoplasty | 1 | 2024 | 9 | 0.050 |
Why?
|
| Aged | 4 | 2026 | 26432 | 0.050 |
Why?
|
| Eyelids | 1 | 2024 | 39 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 28 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 8391 | 0.040 |
Why?
|
| Oculomotor Muscles | 1 | 2022 | 86 | 0.040 |
Why?
|
| Adolescent | 1 | 2021 | 22557 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 334 | 0.040 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 12 | 0.040 |
Why?
|
| Ketosis | 1 | 2021 | 12 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 172 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2021 | 302 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 175 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2026 | 3017 | 0.030 |
Why?
|
| Sinusitis | 1 | 2021 | 221 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 465 | 0.030 |
Why?
|
| Documentation | 1 | 2020 | 202 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2022 | 825 | 0.030 |
Why?
|
| Child | 1 | 2016 | 22693 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1339 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3416 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2020 | 1272 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2786 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 11821 | 0.020 |
Why?
|